Details
Title
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials
Author
Pagano, Gennaro 1
; Trundell, Dylan 2 ; Simuni, Tanya 3 ; Pavese, Nicola 4 ; Marek, Kenneth 5 ; Postuma, Ronald B. 6 ; Shariati, Nima 7 ; Monnet, Annabelle 7 ; Moore, Emma 2 ; Davies, Evan W. 7 ; Svoboda, Hanno 8
; Pross, Nathalie 7 ; Bonni, Azad 9 ; Nikolcheva, Tania 7 ; Zuzuarregui, Rafael; Zanigni, Stefano
1 Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269); University of Exeter Medical School, London, UK (ROR: https://ror.org/03yghzc09) (GRID: grid.8391.3) (ISNI: 0000 0004 1936 8024)
2 Roche Products Ltd, Welwyn Garden City, UK (ROR: https://ror.org/024tgbv41) (GRID: grid.419227.b)
3 Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA (ROR: https://ror.org/019t2rq07) (GRID: grid.462972.c) (ISNI: 0000 0004 0466 9414)
4 Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK (ROR: https://ror.org/01kj2bm70) (GRID: grid.1006.7) (ISNI: 0000 0001 0462 7212)
5 Institute for Neurodegenerative Disorders, New Haven, CT, USA (ROR: https://ror.org/022hrs427) (GRID: grid.429091.7) (ISNI: 0000 0004 5913 3633)
6 Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada (ROR: https://ror.org/05ghs6f64) (GRID: grid.416102.0) (ISNI: 0000 0004 0646 3639)
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269)
8 Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269); Roche Diagnostics GmbH, Penzberg, Germany (ROR: https://ror.org/00sh68184) (GRID: grid.424277.0)
9 Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269)
; Trundell, Dylan 2 ; Simuni, Tanya 3 ; Pavese, Nicola 4 ; Marek, Kenneth 5 ; Postuma, Ronald B. 6 ; Shariati, Nima 7 ; Monnet, Annabelle 7 ; Moore, Emma 2 ; Davies, Evan W. 7 ; Svoboda, Hanno 8
; Pross, Nathalie 7 ; Bonni, Azad 9 ; Nikolcheva, Tania 7 ; Zuzuarregui, Rafael; Zanigni, Stefano1 Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269); University of Exeter Medical School, London, UK (ROR: https://ror.org/03yghzc09) (GRID: grid.8391.3) (ISNI: 0000 0004 1936 8024)
2 Roche Products Ltd, Welwyn Garden City, UK (ROR: https://ror.org/024tgbv41) (GRID: grid.419227.b)
3 Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA (ROR: https://ror.org/019t2rq07) (GRID: grid.462972.c) (ISNI: 0000 0004 0466 9414)
4 Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK (ROR: https://ror.org/01kj2bm70) (GRID: grid.1006.7) (ISNI: 0000 0001 0462 7212)
5 Institute for Neurodegenerative Disorders, New Haven, CT, USA (ROR: https://ror.org/022hrs427) (GRID: grid.429091.7) (ISNI: 0000 0004 5913 3633)
6 Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada (ROR: https://ror.org/05ghs6f64) (GRID: grid.416102.0) (ISNI: 0000 0004 0646 3639)
7 F. Hoffmann-La Roche Ltd, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269)
8 Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269); Roche Diagnostics GmbH, Penzberg, Germany (ROR: https://ror.org/00sh68184) (GRID: grid.424277.0)
9 Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland (ROR: https://ror.org/00by1q217) (GRID: grid.417570.0) (ISNI: 0000 0004 0374 1269)
Pages
241
Section
Author Correction
Publication year
2025
Publication date
2025
e-ISSN
23738057
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3239225026
Copyright
© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.